Kirschner D, Panetta J C
Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor 48109-0620, USA.
J Math Biol. 1998 Sep;37(3):235-52. doi: 10.1007/s002850050127.
A number of lines of evidence suggest that immunotherapy with the cytokine interleukin-2 (IL-2) may boost the immune system to fight tumors. CD4+ T cells, the cells that orchestrate the immune response, use these cytokines as signaling mechanisms for immune-response stimulation as well as lymphocyte stimulation, growth, and differentiation. Because tumor cells begin as 'self', the immune system may not respond in an effective way to eradicate them. Adoptive cellular immunotherapy can potentially restore or enhance these effects. We illustrate through mathematical modeling the dynamics between tumor cells, immune-effector cells, and IL-2. These efforts are able to explain both short tumor oscillations in tumor sizes as well as long-term tumor relapse. We then explore the effects of adoptive cellular immunotherapy on the model and describe under what circumstances the tumor can be eliminated.
大量证据表明，使用细胞因子白细胞介素-2（IL-2）进行免疫治疗可能会增强免疫系统以对抗肿瘤。CD4 + T细胞是协调免疫反应的细胞，它们将这些细胞因子用作免疫反应刺激以及淋巴细胞刺激、生长和分化的信号机制。由于肿瘤细胞起源于“自身”，免疫系统可能无法以有效方式对其进行根除。过继性细胞免疫治疗有可能恢复或增强这些作用。我们通过数学模型说明了肿瘤细胞、免疫效应细胞和IL-2之间的动态关系。这些研究能够解释肿瘤大小的短期波动以及长期的肿瘤复发。然后，我们探讨了过继性细胞免疫治疗对该模型的影响，并描述了在何种情况下肿瘤可以被消除。
